Takemasa Tsuji to Antigens, Neoplasm
This is a "connection" page, showing publications Takemasa Tsuji has written about Antigens, Neoplasm.
Connection Strength
3.048
-
Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancers. PLoS One. 2014; 9(11):e111586.
Score: 0.435
-
Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells. J Immunol. 2012 Apr 15; 188(8):3851-8.
Score: 0.362
-
Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors. PLoS One. 2011; 6(8):e23651.
Score: 0.347
-
Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. J Immunol. 2011 Jan 15; 186(2):1218-27.
Score: 0.332
-
Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination. J Immunol. 2009 Oct 01; 183(7):4800-8.
Score: 0.304
-
A rare population of tumor antigen-specific CD4+CD8+ double-positive aß T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells. J Immunother Cancer. 2019 01 09; 7(1):7.
Score: 0.145
-
Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy. Cancer Immunol Res. 2018 05; 6(5):594-604.
Score: 0.137
-
HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecol Oncol. 2016 07; 142(1):158-162.
Score: 0.120
-
Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One. 2014; 9(8):e104099.
Score: 0.107
-
Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res. 2014 Jan; 2(1):37-49.
Score: 0.103
-
Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. Cancer Immunol Res. 2014 Apr; 2(4):341-50.
Score: 0.102
-
Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res. 2013 Nov; 1(5):340-50.
Score: 0.100
-
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012 Dec 01; 18(23):6497-508.
Score: 0.094
-
Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. Clin Cancer Res. 2012 Oct 01; 18(19):5449-59.
Score: 0.093
-
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010 Apr 27; 107(17):7875-80.
Score: 0.079
-
Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunol Immunother. 2022 Dec; 71(12):2881-2898.
Score: 0.046
-
Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep. 2015 Oct 08; 5:14896.
Score: 0.029
-
Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res. 2013 Oct; 1(4):235-44.
Score: 0.025
-
Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes. Eur J Immunol. 2013 Apr; 43(4):989-1000.
Score: 0.024
-
Inducing efficient cross-priming using antigen-coated yeast particles. J Immunother. 2008 Sep; 31(7):607-19.
Score: 0.018
-
Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood. 2008 Feb 01; 111(3):1404-12.
Score: 0.017
-
Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. J Immunol. 2006 May 15; 176(10):6340-6.
Score: 0.015
-
The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 2004 Sep; 95(9):697-703.
Score: 0.013